General
Preferred name
VATALANIB
Synonyms
Vatalanib succinate ()
Vatalanib (free base) ()
PTK787 free base ()
PTK/ZK free base ()
CGP-79787 free base ()
ZK-222584 free base ()
PTK787, PTK-787, K-222584, CGP-79787, BAY-86-5127, ZK-222584, CGP-79787D, NVP-PTK787 ()
CGP-797870 dihydrochloride ()
ZK-222584 dihydrochloride ()
PTK787 dihydrochloride ()
Vatalanib dihydrochloride ()
Vatalanib (PTK787) 2HCl ()
CGP-79787 dihydrochloride ()
Vatalanib 2HCl ()
Vatalanib (dihydrochloride) ()
BAY-86-5127 ()
CGP-79787 ()
K-222584 ()
NVP-PTK787 ()
PTK-787 ()
PTK787 ()
ZK-222584 ()
ZK222584 ()
PTK787 (dihydrochloride) ()
ZK-222584 (dihydrochloride) ()
CGP-797870 (dihydrochloride) ()
ZK 222584 (cpg-79787) 2HCl ()
Vatalanib (hydrochloride) ()
P&D ID
PD008695
CAS
212141-54-3
212141-51-0
212142-18-2
Tags
available
drug candidate
Drug indication
Solid tumour/cancer
Drug Status
investigational
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Vatalanib is a potent and orally biovailable inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases .
(GtoPdb)
DESCRIPTION
Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
(PKIDB)
DESCRIPTION
Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Potent VEGFR inhibitor; also aromatase inhibitor
(Tocriscreen Plus)
DESCRIPTION
Vatalanib succinate is a potent and orally bioactive VEGFR inhibitor (IC50 =37 and 77 nM for VEGFR-2 and -1, respectively) exhibiting potential antineoplastic activity. Vatalanib binds to the protein kinase domain of VEGFR, and inhibits proliferation, migration and survival of HUVECs in vitro. Vatalanib also inhibits PDGFR-β, c-Kit and c-Fms.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Activator of SUMO-activating enzyme, E1 ligase
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
2
Compound Sets
24
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Clinical kinase drugs
Drug Repurposing Hub
DrugBank
DrugMAP
DrugMatrix
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
PKIDB
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
53
Molecular Weight
346.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
4
cLogP
5.01
TPSA
50.7
Fraction CSP3
0.05
Chiral centers
0.0
Largest ring
6.0
QED
0.56
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzyme-Linked Receptors
Target
VEGFR
PDGFR??
VEGFR1/FLT1
VEGFR2/Flk1
VEGFR2/KDR
VEGFR3/FLT4
EGFR, FLT1, FLT4, KDR, PDGFRB
VEGFR inhibitor
FLT1
FLT4
Pathway
Protein Tyrosine Kinase/RTK
Angiogenesis
Tyrosine Kinase/Adaptors
Chromatin/Epigenetic
Apoptosis
Targets
KDR
MOA
Inhibitor
Angiogenesis Inhibitors
Aromatase Inhibitors
Inhibitors of Signal Transduction Pathways
KIT (C-KIT) Inhibitors
PDGFRbeta Inhibitors
VEGFR-1 (Flt-1) Inhibitors
VEGFR-2 (FLK-1/KDR) Inhibitors
VEGFR-3 (FLT4) Inhibitors
KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Member status
virtual
Source data
